Regen BioPharma, Inc. $RGBP and (RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). The Company will pursue this testing as a joint venture with Zander Therapeutics Inc. Zander Therapeutics, Inc. has been granted an exclusive license by Regen to develop and commercialize Regen's NR2F6 intellectual property for veterinary applications. https://finance.yahoo.com/news/regen-biopharm...00491.html